Volume 4.46 | Nov 29

Prostate Cell News 4.46 November 29, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Prostate Cancer Originating in Basal Cells Progresses to Adenocarcinoma Propagated by Luminal-Like Cells
In a human prostate tissue transformation model, basal cells expressing the oncogenes Myc and myristoylated AKT initiated heterogeneous tumors. Tumors contained features of acinar-type adenocarcinoma with elevated eIF4E-driven protein translation and squamous cell carcinoma marked by activated beta-catenin. [Proc Natl Acad Sci USA] Abstract | Full Article | Press Release
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Identification of a Cyclin D1 Network in Prostate Cancer that Antagonizes Epithelial-Mesenchymal Restraint
Cyclin D1 inactivation reduced cellular proliferation in the murine prostate in vivo and in isogenic oncogene-transformed prostate cancer cell lines. [Cancer Res] Abstract

SOCS2 Correlates with Malignancy and Exerts Growth Promoting Effects in Prostate Cancer
Functionally, suppressor of cytokine signaling 2 (SOCS2) knockdown inhibited prostate cancer cell proliferation and xenograft growth in a CAM assay. Decreased cell growth after SOCS2 downregulation was associated with cell-cycle arrest and apoptosis. [Endocr Relat Cancer] Abstract

Pirin Down-Regulates the EAF2/U19 Protein and Alleviates Its Growth Inhibition in Prostate Cancer Cells
Pirin co-immunoprecipitated with ELL associated factor 2 (EAF2/U19) and the overexpressed Pirin decreased the expression level of EAF2/U19 protein in prostate cancer cell lines LNCaP and PC3. [Prostate] Abstract

EP2 Signaling Mediates Suppressive Effects of Celecoxib on Androgen Receptor Expression and Cell Proliferation in Prostate Cancer
Researchers investigated the suppression of prostate cancer growth by celecoxib and elucidated the biological relevance of the inhibited pathway in prostate cancer cell lines. [Prostate Cancer Prostatic Dis] Abstract

D-Glucuronyl C5-Epimerase Cell Type Specifically Affects Angiogenesis Pathway in Different Prostate Cancer Cells
To investigate the potential cancer-promoting effect of d-glucuronyl C5-epimerase (GLCE) in prostate cancer, GLCE was ectopically re-expressed in morphologically different LNCaP and PC3 prostate cancer cells. [Tumor Biol] Abstract

The Tumor-Suppressive MicroRNA-143/145 Cluster Inhibits Cell Migration and Invasion by Targeting GOLM1 in Prostate Cancer
Scientists investigate the functional significance of the microRNA (miR)-143/145 cluster in prostate cancer (PCa) cells and to identify novel targets regulated by these cluster miRNAs in PCa. [J Hum Genet] Abstract

Activation of RhoA,B,C by Yersinia Cytotoxic Necrotizing Factor (CNFy) Induces Apoptosis in LNCaP Prostate Cancer Cells
Researchers used the bacterial toxins CNFy and CNF1, which specifically and directly activate Rho GTPases by deamidation of a single glutamine. They asked whether these Rho activators could induce apoptosis in LNCaP cells. [Toxins] Abstract | Full Article

MiR-181a Contributes to Bufalin-Induced Apoptosis in PC-3 Prostate Cancer Cells
Bufalin was found to induce the expression of miR-181a, a small non-coding RNA believed to induce apoptosis by repressing its target gene, BCL-2. In prostate cancer PC-3cell line, bufalin-induced apoptosis can be largely attenuated by a miR-181a inhibitor, which blocked bufalin-induced Bcl-2 reduction and caspase-3 activation. [BMC Complement Altern Med] Full Article

CLINICAL RESEARCH

Intermittent Versus Continuous Cyproterone Acetate in Bone Metastatic Prostate Cancer: Results of a Randomized Trial
To compare intermittent treatment versus continuous treatment using cyproterone acetate in bone metastatic prostate cancer patients, investigators conducted an open-label, multicenter randomized trial. [World J Urol] Abstract

Enzalutamide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Chemotherapy and Abiraterone Acetate
Researchers aimed to record prostate-specific antigen (PSA) response and overall survival (OS) for a group of metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide following progression after abiraterone treatment in the post-chemotherapy setting. [Scand J Urol] Abstract

New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
 
REVIEWS
Future Directions in the Prevention of Prostate Cancer
The authors discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention. [Nat Rev Clin Oncol] Abstract

Metastatic Castration-Resistant Prostate Cancer: New Therapies, Novel Combination Strategies and Implications for Immunotherapy
The authors discuss the transformation of the post-docetaxel space in metastatic castration-resistant prostate cancer, highlighting the spectrum of newly approved agents in this setting in the USA and the European Union, as well as summarizing treatments with non-chemotherapeutic mechanisms of action that have demonstrated promising results in recent Phase III trials. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
The Prostate Cancer Foundation Unveils Major Initiative to Improve Accuracy of Laboratory Cancer Studies
The Prostate Cancer Foundation has undertaken a Cell Line Authentication Initiative. This calls for widespread implementation of best practices for cell line authentication. [The Prostate Cancer Foundation] Press Release

Leading Scientists Join BioResearch Open Access Editorial Board under Editor-in-Chief Robert Lanza
Dr. Robert Lanza announced that in addition to the distinguished group of Section Editors, including Alan Russell, James Wilson, and Sir Ian Wilmut, among others, fifteen world renowned experts have joined the new Editorial Board of BioResearch Open Access, including ten members of the National Academy of Sciences and Institute of Medicine. [Mary Ann Liebert, Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposia on Molecular and Cellular Biology: Inflammation, Infection and Cancer
March 9-14, 2014
Whistler, Canada

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Research Associate – Novel Targeted Nanomedicines to Treat Metastatic Prostate Cancer (University of East Anglia)

Postdoctoral Researcher – Prostate Cancer (NUI Galway)

Postdoctoral Fellow – Mechanisms Promoting Castrate Resistant Prostate Cancer (Mount Sinai School of Medicine)

PhD Studentship – Prostate Cancer Research (Cardiff University)

Postdoctoral Fellow – Development and Progression of Prostate Cancer (University of Maryland Baltimore, School of Medicine)

Postdoctoral Fellow / Instructor Position – Endocrine Therapies for Cancer (Baylor College of Medicine)

Experienced Researcher Position – Molecular Biology (ServiceXS B.V.)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Prostate Cell News: Archives | Events | Contact Us